The team of Professor Han Weidong from the Department of Biotherapy of the First Medical Center of the PLA General Hospital, which lasted for more than two years, has united with 7 institutions at home and abroad. Aiming at the blind spot in the understanding and treatment of the main adverse event of CAR-T treatment-cytokine release syndrome, the innovative proposal of "local The new concept and hypothesis of "cytokine release syndrome", and formulate the corresponding clinical management path based on the management model created by the department. Recently, the research results were published in STTT magazine (IF: 13.5). The authors are Liu Yang, Wei Jianshu, Zhang Yajing, Wang Chunmeng, etc.
With the approval of CAR-T cells for clinical use in the United States and Europe, the cognition and clinical management of cytokine release syndrome, the main related adverse event of CAR-T, has attracted more and more attention. Professor Han Weidong’s team found that there are significant differences in the clinical manifestations of cytokine release syndrome after CAR-T cell therapy between patients with different tumors. However, the existing domestic and foreign guidelines do not have differentiated understanding and treatment, resulting in There are many blind spots in clinical management and treatment.
As the first team to carry out CAR-T cell therapy clinical research in China, Professor Han Weidong’s team has carried out a series of CAR-T-related basic and clinical research since 2013, completed a number of pioneering work on “international first cases” and became One of the most representative and authoritative institutions in this field in China. After several years of research and practice, the team innovatively proposed the concepts of "systemic cytokine release syndrome" and "local cytokine release syndrome", and subdivided the entire process into four stages, based on cell dynamics. The principle puts forward a new model hypothesis for the formation of cytokine release syndrome and validates it. Based on the principle, the corresponding clinical treatment and control measures are re-formulated, which greatly reduces the severity and fatal risk of cytokine release syndrome.
This achievement represents that my country's independent innovative clinical cognition of CAR-T cell therapy technology has been recognized internationally. The promotion of new clinical management models to serve the clinical frontline is expected to change the international status quo of cytokine release syndrome treatment strategies in the future.